Atturos is thrilled to have been included in Silicon Republic’s list of 23 tech start-ups to watch out for in 2023. 

“As we head into the new year, we have selected some of the most promising Irish start-ups from our series that tech investors and entrepreneurs should keep an eye out for”.

We’re delighted to have been profiled by Silicon Republic, Ireland’s No 1 resource for science and technology news, updating on our recent activities and future direction. Atturos CEO Robert Perryman and CSO Steve Pennington share their vision for the future of clinical diagnostics, and how Atturos plans to help patients and doctors with their decision-making.

In 2021 Atturos secured additional funding which has resulted in the generation of several new roles within the company.  To facilitate the expansion of the team the Atturos office has now relocated to a new, larger, dedicated space.

To view current job opportunities visit our careers page! 

“In this expert webinar, Prof. Stephen Pennington, Dr. Orla Coleman, and Dr. James Waddington outline the importance of better diagnostic tests and data to address unmet clinical needs in chronic diseases. They explain how this diagnostic data can be obtained through an integrated workflow that enables simplified, robust, reproducible, and cost-effective analysis of readily collected human samples. Using supporting illustrative data, the Atturos team demonstrate how it will be possible to use clinical research measurements for precision medicine”

Orla Coleman, Atturos Senior Scientist, presented results from the recently completed Atturos GRAPPA- Lilly project “Identification of serum protein biomarkers at baseline to distinguish radiographic progressors from non-progressors in patients with active Psoriatic Arthritis” at the IFPA 6th WPPAC. Orla’s presentation introduced the unmet clinical need to identify Psoriatic arthritis patients who are risk of progression to radiographic damage. The presentation outlines the work Atturos has undertaken to use targeted proteomics and data analysis by machine learning methods to identify a biomarker signature and algorithm that may predict disease progression.

Led by Atturos CSO Steve Pennington, with contributions from Senior Scientist James Waddington, ‘Biomarkers for improved management of prostate cancer’ has been selected as a feature article in Clinical Laboratory International (CLI). The article describes challenges in the clinical management of prostate cancer, limitations to current screening and diagnostic strategies and the future of biomarker tests for personalized prostate cancer patient care. To read the full article download a copy here, or click on the link below to visit CLI

BMC Clinical Proteomics, part of Springer Nature, selected "Clinical proteomics for prostate cancer" as the feature article for January and February 2021. The review, led by Atturos CSO Steve Pennington, discusses high throughput proteomic technologies as a potential solution for the current challenges faced in diagnosing and treating prostate cancer.

Steve presented on the "Development and Delivery of Advanced Protein Tests for an Era of Precision Medicine". For further information on PSI 2020 visit their website!

The Atturos management team have undertaken and completed a business case analysis for the commercial feasibility of a serum protein assay – PsARADx. The assay is protected under UCD patent application WO 2020/025721and provides “A method of diagnosing or prognosing psoriatic arthritis”.  The analysis undertaken included engagement with key stakeholders. Atturos is now in negotiations with UCD to acquire a license to the patent.

Atturos founder, Steve Pennington, and Senior Scientist, James Waddington, played a key role in publication of the Human Proteome Project’s blueprint of the Human Proteome 'A high-stringency blueprint of the human proteome'. 

New €16 million EU and industry-supported international research consortium aims to improve obesity treatment and change the narrative around obesity

Twenty-nine leading partners from civil society, academia and industry in 12 countries have joined forces to better understand obesity and optimise future treatment

James Waddington (MBiolSci, PhD) joins the Atturos Scientific Team as a Senior Scientist!

Orla Coleman (Atturos) and Scott Bringans (PILL) present the poster "PromarkerD as an immunoaffinity mass spectrometry assay for diabetic kidney disease"

Atturos are pleased to announce that the European patent filing (EP3084444) derived from International patent application (PCT/EP2014/078914) for “Prostate Cancer Biomarkers” has been granted. The patent supports the on-going protection of OCProDx. 

The new European collaborative project SCREENED aims to develop three-dimensional (3D)
cellbased in vitro tests to better characterize the effects of endocrine disruptors on thyroid gland function.

Twelve start-ups pitched their new technology solutions to investors at the 10th annual innovation showcase event BIG IDEAS. Atturos were shortlisted and presented OCProDx to an invited audience of Irish research and business communities 

Steve Pennington invited to join Oxford Global Biomarkers Directors Club and presents at 13th Annual Congress, Manchester, U.K.

Atturos development and delivery of MassSpec based multiplexed biomarker assays was presented by Steve Pennington at a lunchtime workshop hosted by Agilent at the Mass Spectrometry Applications to the Clinical Lab 10th Annual Conference Palm Springs, California, U.S.A.

Listen to Stephen Pennington telling the story of Atturos...

We are delighted to announce that Professor Jennifer Van Eyk has today joined the Atturos Advisory Board. 

Members of the Atturos team attended the 2nd Annual John Fitzpatrick Prostate Cancer Conference last week in the Aviva Stadium in Dublin.

Atturos CEO Robert Perryman had the opportunity to introduce Atturos to the investment community at NOVA UCD Investors Day yesterday.

It was a fantastic event and so wonderful to be back meeting people face to face again.

"This webinar explorers challenges faced by clinical researchers seeking to improve chronic disease testing. Hear experts form Atturos, a leading clinical diagnostics company, discuss the importance of high-quality clinical data and the role improved analytical workflows and advanced tests play in improving precision medicine outcomes."

“In this first episode, Prof Oliver FitzGerald and Atturos CSO Prof Stephen Pennington talk to Gráinne O’Leary about psoriatic arthritis, how it’s diagnosed, its symptoms and impact, and patients’ unmet needs. They also discuss HIPPOCRATES the recently funded IMI (Innovative Medicines Initiative) public private research consortium which aims to address unmet needs in psoriatic disease and develop personalised treatment options for those affected.”

Steve Pennington (Atturos CSO) and Oliver FitzGerald (Atturos Clinical Leadership Team and GRAPPA Co-President) were joined by senior scientists James Waddington and Orla Coleman to present project updates at the international GRAPPA 2021 meeting. The presentation provided GRAPPA network with an update of progress on two important strategic research projects with Lilly and Pfizer.

Steve was the invited Opening Keynote speaker at TECHNOLOGY NETWORKS, Advances in Proteomics & Metabolomics 2021 – from research to the clinic. The event, attracting over 1,100 registrants, brought together world leading experts to discuss the role of proteomics approaches in understanding disease and the development of novel clinical biomarkers. 

Read our latest publication “Identification and Evaluation of Serum Protein Biomarkers Which Differentiate Psoriatic from Rheumatoid Arthritis”.

Atturos are pleased to announce that following the completion of a business case analysis, it has negotiated a worldwide exclusive license agreement for patent WO 2020/025721 “A method of diagnosing or prognosing psoriatic arthritis” from University College Dublin. The patent underpins the serum protein ‘PsARADx’ assay which can discriminate patients with psoriatic arthritis from those with rheumatoid arthritis. Atturos is looking forward to beginning the next steps in developing the assay which has the potential to improve psoriatic arthritis patient outcomes.

Clinical proteomics for prostate cancer: understanding prostate cancer pathology and protein biomarkers for improved disease management

Read our latest application note "From Nanoflow to Standard Flow LC/MS for Routine Quantitative Plasma Proteomics in Diabetic Kidney Disease Research".

Applying precision medicine to unmet clinical needs in psoriatic disease.

SCREENED: A Multistage Model of Thyroid Gland Function for Screening Endocrine-Disrupting Chemicals in a Biologically Sex-Specific Manner 

Founder and Chief Scientific Officer Prof. Stephen Pennington presents Atturos work at the Clinical and Pharmaceutical Solutions through Analysis Symposium in Philadelphia, Pennsylvania, U.S.A on the 28th of October 2019.

Diagnostic Blood Test to Predict Onset of Diabetic Kidney Disease One Step Closer to Launch Across Europe.

Orla Coleman (BSc, PhD) joins the Atturos Scientific Team as a Senior Scientist!

Prof. Stephen Pennington was presented with the NovaUCD 2018 innovation award...

Atturos is pleased to announce it has begun a significant collaboration with Merck KGaA. “The projects sees Atturos developing important LC-MS workflows for Merck KGaA and marks what both companies hope will be a series of ongoing collaborative projects” notes Dave Corr, CEO Atturos Ltd.

Steve presents Atturos’ MRM workflows at the Analytica Conference, Munich, Germany.

Atturos Founder and CSO Stephen Pennington hosts the 16th Human Proteome Organisation World Congress in Dublin. 

Atturos Stephen Pennington features in The Irish Times announcing the finalists of the AIBstart-up Academy

The third and final Atturos brainstorming session was focussed on Business Development and was held today in NovaUCD...

As part of our continuous clinical and market research efforts Atturos CEO Stephen Pennington attended the European Association of Urology Annual Meeting this past weekend.

Atturos CSO Steve Pennington presented the latest data obtained as part of on-going GRAPPA-Pfizer study at the American College of Rheumatology Meeting (ACR Convergence) held in Philadelphia, USA 11-14th November.  The poster presentation on “Evaluation of Candidate Protein Biomarkers to Predict Treatment Response in Patients with Psoriatic Arthritis” outlined the development of a blood protein signature measured by MRM and associated algorithm that may be predict which patients will respond to JAK inhibitor treatment.

To view the full abstract click the link below:

The recently started HIPPOCRATES EU consortium and Government of Ireland (DTIF) project, PERSONA, will see Atturos working with Neoteryx to investigate microsampling devices for use in protein based advanced diagnostic testing. In this podcast, Atturos CSO Steve Pennington discusses the use of microsampling in proteomics & multi-centre studies.

Oliver FitzGerald (Atturos Clinical Leadership Team and GRAPPA Co-President) has been recognised as a Master of the American College of Rheumatology. This is one of the highest honours the College bestows to members who have made outstanding contributions to the field of rheumatology through scholarly achievement and/or service to their patients, students, and profession. Congratulations Oliver!

HIPPOCRATES combines 26 different research partners, SMEs, pharmaceutical companies, and patient organisations in promoting early identification and improving outcomes for patients with psoriatic arthritis. The consortium is co-led by Stephen Pennington, Atturos CSO, and Oliver FitzGerald, Atturos Head of Clinical Affairs Rheumatology. Download a copy of the full press release here, and visit the website for more information

Atturos recent funding successes and the future directions of our product development have appeared in a Sunday Business Post article ‘Making it Work: Medical start-up Atturos gets €700k for arthritic research’. In the article Steve, Atturos founder and CSO, discusses the next stages in Atturos business development including the recruitment of a CEO. To read the article click below.

Atturos is delighted to announce it has secured €1.57m funding from the third round of the Disruptive Technologies Innovation Fund. In collaboration with Agilent Technologies Ireland, Neoteryx and UCD, the consortium will develop the first innovative plasma sampling device for inflammatory diseases. We are excited to move PERSONA (Patient Centric Sampling for a New Diagnostic Pathway) forward, and look forward to updating you all soon with further information!

We all know it's been a challenging year, so we used the 1st of December as an excuse to decorate the office, put on our festive jumpers and switch on the Atturos office Christmas tree lights! Thanks to our fantastic research assistant Joy for doing the honours.

Following the grant of the “Prostate Cancer Biomarkers” patent in Europe, Atturos have now been granted a US wide patent (US 15/106,582) derived from International patent application (PCT/EP2014/078914).

Read our latest publication "A robust multiplex immunoaffinity mass spectrometry assay (PromarkerD) for clinical prediction of diabetic kidney disease". This work represents a collaborative effort between the Atturos Team, Proteomics International (Perth) and Sydney Mass Spectrometry.

As our team and portfolio are quickly expanding, our website needed to grow with us... welcome to the new look website! If you have any feedback, please let us know!

"20 health and medtech start-ups with their finger on the pulse"

100 Hot Start Ups – The Sunday Business Post . The companies driving Irelands entrepreneurial edge.

​

Atturos Ltd is delighted to be recognised amongst The Sunday Business Post’s latest list of Irish entrepreneurial companies.

Joy Zhou (BSc, MSc) joins the Atturos Scientific Team as a Research Assistant!

In February 2019 the SCREENED project was kicked off following the launch of the EURION cluster in Brussels, Belgium

Proteomics International and Irish clinical diagnostics company Atturos have signed a Memorandum of Understanding that will see the companies join forces to develop novel diagnostic tests for the European region.

Atturos Founder and Chief Scientific Officer Steve Pennington presents at an Agilent hosted press briefing during the American Association for Cancer Research Annual Meeting 2018.

Identification and evaluation of serum protein biomarkers for organ confined prostate cancer.

The Atturos lab opens in the Conway Institute, UCD, Dublin. See what we are focussing on!

CSO, Stephen Pennington was in Rome for the signing of the agreement.

Last Friday May 13th Atturos hosted a Clinical and Technical Brainstorming session in NovaUCD as part of our market analysis to obtain and evaluate customer and end user attitudes towards the OCProDx test...